Tracks inner eye nerve cell changes over time in adults with retinitis pigmentosa
Follows inner eye nerve cells over time in adults with retinitis pigmentosa.
Plain-language title generated from the registry record
Registry title: Prospective Exploratory Cohort Study on Ganglion Cell Degeneration in Retinitis Pigmentosa Patients
Key facts
- Where
- Göttingen, GermanySee the site
Where in Germany
- EKFZ Else Kroener Fresenius Center for Optogenetic Therapies, University Medical Center GoettingenGöttingen, GermanyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Medical Center Goettingen
- Trial code
- NCT07056738
- Record updated
- 9 July 2025
- Original description
The aim of this study is an explorative prospective observation of retinal ganglion cell degeneration and/or inner retina degeneration in Retinitis pigmentosa patients. The rate and patterns of progression will be correlated to the outer retina layers as well as clinical and genetic data of patients. Secondary goal is to determine potential parameters for optogenetic treatment eligibility.Read full original descriptionShow less
Longitudinal Characterization of Inner Retina Health in Low Vision Retinitis Pigmentosa Patients to Optimize Retinal Ganglion Cell-based Optogenetic Vision Restoration Therapy
The aim of this study is an explorative prospective observation of retinal ganglion cell degeneration and/or inner retina degeneration in Retinitis pigmentosa patients. The rate and patterns of progression will be correlated to the outer retina layers as well as clinical and genetic data of patients. Secondary goal is to determine potential parameters for optogenetic treatment eligibility.
Inclusion: genetically diagnosed Retintis pigmentosa; minimum age of 18 years (legal adult age in Germany); patient consent for study participation.
Exclusion: lack of capacity to consent in participation of study (unconsciousness, mental capacity, mental illness); presence of additional retinal diseases; age under 18 years; reduced cooperation during imaging or examination; insufficient imaging quality due to hazy media (cornea, lense).